Lukas Hockman, MD
Urology · Kansas City, MONPI 1891177226
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Urogen Pharma, Inc. at 38.7% of the total.
Across 138 payments — averaging $98.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$5K
- Boston Scientific$3K
- Profound Medical Corp.$2K
- Histosonics, Inc.$560
- Medtronic$454
- Intuitive Surgical$259
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$4,06330%
- Travel & lodging$3,87228%
- Food & beverage$5,57841%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 16 | $5,273 |
| Boston Scientific | 31 | $3,417 |
| Profound Medical Corp. | 2 | $1,528 |
| Histosonics, Inc. | 2 | $560 |
| Medtronic(2 entities) | 5 | $454 |
| Intuitive Surgical | 4 | $259 |
| Ferring Pharmaceuticals Inc. | 6 | $172 |
| C. R. Bard, Inc. & Subsidiaries | 9 | $170 |
| Cook Medical LLC | 2 | $136 |
| Immunitybio, Inc. | 5 | $135 |
| Sumitomo Pharma America, Inc. | 2 | $133 |
| Johnson & Johnson | 2 | $123 |
| Neotract Inc. | 1 | $103 |
| Antares Pharma, Inc. | 6 | $103 |
| Teleflex LLC | 5 | $102 |
| Astellas Pharma US Inc | 1 | $100 |
| Conmed Corporation | 1 | $83 |
| AbbVie | 5 | $80 |
| TELA Bio, Inc. | 1 | $56 |
| Tolmar, Inc. | 3 | $54 |
| Olympus America Inc. | 3 | $54 |
| Endo USA, Inc. | 2 | $48 |
| Progenics Pharmaceuticals, Inc. | 2 | $48 |
| Blue Earth Diagnostics | 2 | $39 |
| BD | 2 | $38 |
| Urovant Sciences Inc | 2 | $35 |
| Verity Pharmaceuticals Inc. | 2 | $30 |
| Angiodynamics, Inc. | 1 | $29 |
| Novo Nordisk | 1 | $28 |
| Photocure Inc | 2 | $28 |
| Mimedx Group, Inc. | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $26 |
| Aroa Biosurgery Incorporated | 1 | $25 |
| Pfizer | 1 | $21 |
| Procept Biorobotics Corporation | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Brainlab, Inc. | 1 | $15 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZUSDURI$2,475
- Tulsa-Pro$1,528
- AMS$1,390
- GENERAL KIDNEY STONE DISEASE$1,173
- JELMYTO$601
- Signia$179
- rezum Generator$173
- LigaSure$122
- GEMTESA$119
- UroLift$103
How this compares
$13,612 in reported general payments places this provider in the 85th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 90 | $75,413 |
| MyrbetriqMirabegron | 87 | $61,020 |
| ElmironPentosan Polysulfate Sodium | 14 | $15,391 |
| Tamsulosin Hcl | 417 | $5,402 |
| Trospium Chloride ErTrospium Chloride | 18 | $4,709 |
| Finasteride | 201 | $2,819 |
| Estradiol | 32 | $2,207 |
| Silodosin | 14 | $1,589 |
| Methenamine Hippurate | 22 | $1,551 |
| Cefdinir | 48 | $793 |
| Potassium Citrate ErPotassium Citrate | 16 | $533 |
| Dutasteride | 17 | $466 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 19 | $403 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $307 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $133 | $75,41390 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $61,02087 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 urology providers in Missouri.
Other urology in Kansas City
- Samuel KuykendallKansas City$141K
- Donald NeffKansas City$27K
- Patrick ProbstKansas City$14K
- Daniel HolmesKansas City$9K
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.